Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sees Large Increase in Short Interest

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 52,800 shares, a growth of 58.6% from the February 28th total of 33,300 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 123,500 shares, the short-interest ratio is currently 0.4 days.

Shionogi & Co., Ltd. Stock Performance

OTCMKTS:SGIOY traded down $0.08 during mid-day trading on Wednesday, hitting $7.48. The stock had a trading volume of 39,608 shares, compared to its average volume of 131,276. The stock has a market capitalization of $12.73 billion, a price-to-earnings ratio of 13.06, a P/E/G ratio of 2.37 and a beta of 0.23. The company has a 50 day simple moving average of $7.43 and a 200-day simple moving average of $7.48. Shionogi & Co., Ltd. has a 52 week low of $6.22 and a 52 week high of $8.36. The company has a current ratio of 7.64, a quick ratio of 7.01 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $0.16 earnings per share for the quarter. Shionogi & Co., Ltd. had a return on equity of 12.02% and a net margin of 35.53%. On average, research analysts expect that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.